PARP1 and ovarian cancer: Based on these results, a clinical trial testing the combination of the PARP inhibitor olaparib and a PI3K inhibitor (pan-P110 BKM-120 or P110α specific BYL719) was initiated for breast and ovarian cancer (NCT01623349).